An Open Enrollment Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
Public ClinicalTrials.gov record NCT00945906. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Prospective, Multicenter, Open Enrollment Study of Human Plasma-Derived Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency
Study identification
- NCT ID
- NCT00945906
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- CSL Behring
- Industry
- Enrollment
- 61 participants
Conditions and interventions
Conditions
Interventions
- FXIII Concentrate (Human) (FXIII) Biological
Biological
Eligibility (public fields only)
- Age range
- Not listed
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 31, 2009
- Primary completion
- Jul 31, 2011
- Completion
- Jul 31, 2011
- Last update posted
- Oct 11, 2012
2009 – 2011
United States locations
- U.S. sites
- 25
- U.S. states
- 17
- U.S. cities
- 25
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Study Site | Dothan | Alabama | 36301 | — |
| Study Site | Oakland | California | 94609 | — |
| Study Site | Orange | California | 92868 | — |
| Study Site | San Francisco | California | 94118 | — |
| Study Site | Stockton | California | 95204 | — |
| Study Site | Fort Myers | Florida | 33908 | — |
| Study Site | Miami | Florida | 33136 | — |
| Study Site | St. Petersburg | Florida | 33701 | — |
| Study Site | New Orleans | Louisiana | 70121 | — |
| Study Site | Boston | Massachusetts | 02115 | — |
| Study Site | Ann Arbor | Michigan | 48109 | — |
| Study Site | Detroit | Michigan | 48201 | — |
| Study Site | Kansas City | Missouri | 64108 | — |
| Study Site | Las Vegas | Nevada | 89109 | — |
| Study Site | Lebanon | New Hampshire | 03756 | — |
| Study Site | Albany | New York | 12208 | — |
| Study Site | New York | New York | 10065 | — |
| Study Site | Chapel Hill | North Carolina | 27599 | — |
| Study Site | Columbus | Ohio | 43205 | — |
| Study Site | Hershey | Pennsylvania | 17033 | — |
| Study Site | Sioux Falls | South Dakota | 57105 | — |
| Study Site | Nashville | Tennessee | 37232 | — |
| Study Site | Dallas | Texas | 75390 | — |
| Study Site | Houston | Texas | 77030 | — |
| Study site | Milwaukee | Wisconsin | 53223 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00945906, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 11, 2012 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00945906 live on ClinicalTrials.gov.